Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15121547 | 1.00 | SRD5A1 (0.38) | SRD5A1CDK5CDK5R1KMT2ABCHE | |
| SCHEMBL3869928 | 1.00 | SRD5A1 (0.38) | SRD5A1CDK5CDK5R1KMT2ABCHE | |
| SCHEMBL8380414 | 0.80 | SRD5A2 (0.45) | KMT2ASRD5A2 | |
| SCHEMBL8014771 | 0.80 | SRD5A2 (0.45) | KMT2ASRD5A2 | |
| SCHEMBL8079491 | 0.79 | SRD5A2 (0.37) | SRD5A1CYP19A1SRD5A2 | |
| SCHEMBL8079488 | 0.79 | SRD5A2 (0.37) | SRD5A1CYP19A1SRD5A2 | |
| SCHEMBL518237 | 0.78 | SRD5A2 (0.46) | SRD5A1KMT2ASRD5A2 | |
| SCHEMBL518238 | 0.78 | SRD5A2 (0.46) | SRD5A1KMT2ASRD5A2 | |
| SCHEMBL536894 | 0.78 | CDK5 (0.49) | CDK5CDK5R1CYP19A1 | |
| SCHEMBL994646 | 0.78 | CDK5 (0.49) | CDK5CDK5R1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1622567-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1622567-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100874-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | SRD5A1 42/4885CDK5 2978/4885CDK5R1 1189/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | SRD5A1 42/4885CDK5 2978/4885CDK5R1 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.